Evelo Biosciences

$16.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.30 (+1.83%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell EVLO and other stocks, options, and ETFs commission-free!

About EVLO

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA. The listed name for EVLO is Evelo Biosciences, Inc. Common Stock.

CEO

Balkrishan Gill

Employees

Headquarters

Cambridge, Massachusetts

Founded

2014

Market Cap

647.18M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

249.20K

High Today

$17.57

Low Today

$15.11

Open Price

$15.71

Volume

221.71K

52 Week High

$17.71

52 Week Low

$3.01

Collections

EVLO Earnings

-$0.78

-$0.52

-$0.26

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 11, Pre-Market